NewAmsterdam Pharma Company N.V. Warrant (NAMSW NASDAQ) stock market data APIs
$7.9564
0.42(5.3%)
as of June 30, 2025
Try our APIs with
free plan!
NewAmsterdam Pharma Company N.V. Warrant Financial Data Overview
Price chart is built with
Anychart
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Prev. Close
7.9564
Open
8.3769
High
8.6451
Low
7.9564
52 wk Range
5.45-16.75
Market Cap
0
Revenue
47 140 K
Beta
-0.025
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewAmsterdam Pharma Company N.V. Warrant data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Warrant Fundamental Data
NewAmsterdam Pharma Company N.V. Warrant Fundamental data includes:
- Net Revenue: 47 140 K
- EBITDA: -189 582 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get NewAmsterdam Pharma Company N.V. Warrant End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Warrant News
New
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14%
Market forces rained on the parade of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shareholders today, when the analysts downgraded their forecasts for this year. There was a fairly draconian cut to...
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
NewAmsterdam Pharma N.V. -- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer�...
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage...
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma N.V. NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
